Eli Lilly has revealed plans for a significant $4.5 billion investment aimed at establishing a new manufacturing and development center, poised to support innovative treatments from the research phase through to clinical trials. Set to be located in Indiana, this cutting-edge facility is expected to commence operations in late 2027 and will integrate advanced research, manufacturing, and modern production methodologies. The newly proposed center, aptly named Medicine Foundry, will serve a critical role in scaling supply for clinical studies, thereby supporting Eli Lilly's expanding therapeutic pipeline.
Chief Executive David Ricks commented, "As we accelerate our work to discover new medicines for the toughest diseases, we're continuing to invest in state-of-the-art infrastructure to support our growing pipeline." The establishment of this complex is anticipated to enhance the pharmaceutical giant’s process development and manufacturing efficiencies, ultimately speeding the delivery of next-generation medicines.
Furthermore, the facility is projected to decrease both costs and the environmental impact associated with pharmaceutical production. Medicine Foundry will be capable of producing a variety of molecular therapies, including drug substances for small molecules, biologics, and nucleic acid therapies.
Notably, the novel technologies developed within this facility will be transferred to other Lilly manufacturing sites for comprehensive production scaling. Upon its operational launch, the center is expected to create approximately 400 high-skilled full-time positions, significantly contributing to local employment opportunities and technological advancement in drug manufacturing..